His primary scientific interests are in Hsp90, Biochemistry, Cell biology, Stereochemistry and Hsp90 inhibitor. He specializes in Hsp90, namely Geldanamycin. His work in the fields of Biochemistry, such as Novobiocin, Natural product, Enzyme inhibitor and Enzyme, overlaps with other areas such as DNA gyrase.
Brian S. J. Blagg works mostly in the field of Natural product, limiting it down to concerns involving Structure–activity relationship and, occasionally, Molecular conformation, MEDLINE and Topoisomerase-II Inhibitor. In the subject of general Cell biology, his work in Chaperone and Phosphorylation is often linked to Wee1 and Eukaryotic translation elongation factor 1 alpha 1, thereby combining diverse domains of study. His Stereochemistry research is multidisciplinary, incorporating elements of Diels alder, Uncompetitive inhibitor and Cycloaddition, 1,3-Dipolar cycloaddition.
Brian S. J. Blagg focuses on Hsp90, Biochemistry, Stereochemistry, Novobiocin and Cell biology. He works on Hsp90 which deals in particular with Geldanamycin. His Natural product, Binding site, Cell growth and Enzyme inhibitor study in the realm of Biochemistry interacts with subjects such as Hsp90 inhibitor.
The study incorporates disciplines such as Stereoisomerism, Ring, Amide, Structure–activity relationship and Chemical synthesis in addition to Stereochemistry. In his research, Combinatorial chemistry is intimately related to Coumarin, which falls under the overarching field of Novobiocin. His work on Endoplasmic reticulum and Plasma protein binding as part of general Cell biology study is frequently connected to Myocilin and Heat shock, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Brian S. J. Blagg mostly deals with Hsp90, Biochemistry, Cell biology, Pharmacology and Stereochemistry. Hsp90 is integrated with Novobiocin, Chaperone, Combinatorial chemistry, Sugar and Protein folding in his study. His studies deal with areas such as Structure–activity relationship and Cell growth as well as Novobiocin.
His research in the fields of Natural product, Binding site and In vitro overlaps with other disciplines such as Troponin complex and Troponin T. His Pharmacology study integrates concerns from other disciplines, such as Peripheral neuropathy and Cancer. The concepts of his Stereochemistry study are interwoven with issues in Biological evaluation, Neuroprotection, Coumarin and Amide.
His main research concerns Hsp90, Biochemistry, Cell biology, Endoplasmic reticulum and Glucose-regulated protein. His Hsp90 research encompasses a variety of disciplines, including Sugar and Novobiocin. His research investigates the link between Novobiocin and topics such as Clinical evaluation that cross with problems in Cell growth.
His primary area of study in Biochemistry is in the field of Chaperone. His biological study spans a wide range of topics, including Natural product, Plasma protein binding and Drug discovery. His study in Cell biology is interdisciplinary in nature, drawing from both Neurotoxicity and Activator.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Alison Donnelly;Brian S J Blagg.
Current Medicinal Chemistry (2008)
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.
Joseph A. Burlison;Len Neckers;Andrew B. Smith;and Anthony Maxwell.
Journal of the American Chemical Society (2006)
Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Brian S. J. Blagg;Timothy D. Kerr.
Medicinal Research Reviews (2006)
Hsp90 inhibitors identified from a library of novobiocin analogues.
Xiao Ming Yu;Gang Shen;Len Neckers;Helen Blake.
Journal of the American Chemical Society (2005)
E. coli MEP synthase: steady-state kinetic analysis and substrate binding.
Andrew T. Koppisch;David T. Fox;Brian S. J. Blagg;C. D. Poulter.
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mehdi Mollapour;Shinji Tsutsumi;Alison C. Donnelly;Kristin Beebe.
Molecular Cell (2010)
Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents
Huiping Zhao;Alison C. Donnelly;Bhaskar R. Kusuma;Gary E. L. Brandt.
Journal of Medicinal Chemistry (2011)
Gedunin, a Novel Hsp90 Inhibitor: Semisynthesis of Derivatives and Preliminary Structure–Activity Relationships
Gary E. L. Brandt;Matthew D. Schmidt;Thomas E. Prisinzano;Brian S. J. Blagg.
Journal of Medicinal Chemistry (2008)
The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.
Alison C. Donnelly;Jared R. Mays;Joseph A. Burlison;John T. Nelson.
Journal of Organic Chemistry (2008)
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Joseph A. Burlison;Christopher Avila;George Vielhauer;Donna J. Lubbers.
Journal of Organic Chemistry (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: